luisenriquereyes | 1 points
Research paper on Nature.com published January 20, 2021: Findings suggest the potential of Ivermectin to inhibit the SARS-CoV-2 replication... could be a potential drug candidatePaper published January 20, 2021:
Summary discussion of the research:
Interestingly, one of the off-target drugs (OTDs), Ivermectin was able to inhibit more than 85% (almost completely) of 3CLpro activity in our in vitro enzymatic assay with an IC50 value of 21 µM. These findings suggest the potential of Ivermectin to inhibit the SARS-CoV-2 replication. In support of this, a recent finding suggested that ivermectin (5 µM) inhibited the replication of live SARS-CoV-2 isolated from Australia (VIo1/2020) in Vero/hSLAM cells23. They found that 5000-fold viral counts were reduced in 48 hr in both culture supernatant (release of new virion: 93%) as well as inside the cells (unreleased and unassembled virion: 99.8%) when compared to DMSO treated infected cells. Interestingly, this study reported the IC50 value of ivermectin as 2.5 µM23, whereas, we observed an IC50 value of 21 µM (10-fold increase)...
..in this study, we have reported that Ivermectin inhibits the enzymatic activity of SARS-CoV-2 3CLpro and thus may potentially inhibit the replication of RNA viruses including SARS-CoV-2. These studies suggest that Ivermectin could be a potential drug candidate to inhibit the SARS-CoV-2 replication and the proposed anti-viral mechanism of ivermectin presented in Fig. 8 and in vivo efficacy of ivermectin towards COVID-19 is currently been evaluated in clinical trials (ClinicalTrials.gov Identifier: NCT04438850).
This research paper was published on Nature.com by Nature Research, a leading international weekly journal of science first published in 1869. On their site the say: "Every month, nine million people read news, analysis and commentary on nature.com."